EarningsWAT’s 2Q24 guide came in below expectations, despite increasingly positive customer conversations and the potential for a strong LC replacement cycle given the pent-up demand of aging instrument fleets, particularly throughout China as stimulus talks are positive.
Market PerformanceChina weakness was broad-based across pharma, industrial, and academic/government markets, with China declining ~28% overall.
RevenueWAT pointed 2Q revenue/EPS below Street, implying a steep 2H24 ramp compared to historical trends.